CVRx, Inc.

NASDAQ•CVRX

CEO: Mr. Kevin Hykes

Sector: Healthcare

Industry: Medical - Devices

Listing Date: 2021-06-30

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Contact Information

9201 West Broadway Avenue, Suite 650, Minneapolis, MN, 55445, United States

763-416-2840

www.cvrx.com

Market Cap

$207.07M

P/E (TTM)

-3.9

25.9

Dividend Yield

52W High

$13.34

52W Low

$4.30

52W Range

39%

Rank61Top 91.5%

2.0

F-Score

Modified Piotroski Analysis

Based on 6-year fundamentals

Weak • 2 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2020-2025

Financial Dashboard

Q4 2025 Data

Revenue

$16.02M+0.00%

4-Quarter Trend

EPS

-$0.46+0.00%

4-Quarter Trend

FCF

-$9.83M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Revenue Growth 10% Revenue reached $56.7M USD, growing 10% over prior year; U.S. sales up 10% to $51.9M USD.

Gross Margin Improvement Gross profit increased 13% to $48.3M USD; Gross margin improved to 85% from 84% due to efficiency.

Operating Loss Narrowed Operating loss narrowed 14% to $51.3M USD; Net loss decreased 11% to $53.3M USD for 2025.

Sales Territory Expansion U.S. implanting centers grew to 252 from 223; U.S. sales territories expanded to 53 from 48.

Risk Factors

Sustained Operating Losses History of significant net losses ($53.3M USD in 2025) expected to continue, impacting capital raising ability.

Single Product Dependency Highly dependent on Barostim sales; failure to increase U.S. market acceptance materially affects liquidity and results.

Limited Sales Experience Limited commercial sales experience; inability to retain or grow sales capabilities prevents sustained increasing product revenue.

Supply Chain Vulnerability Reliance on limited third-party suppliers for critical components creates vulnerability to shortages and performance degradation.

Outlook

Expanded Clinical Trial Initiated BENEFIT-HF trial in Jan 2026 to evaluate expanded population; success could raise U.S. market to $30.5B.

Future Financing Secured Borrowed $10.0M in Jan 2026; maintains ATM capacity up to $50.0M for future commercialization investments.

R&D Focus Areas Near-term R&D focuses on technological advancement; long-term goal is expanding indications to hypertension and arrhythmias.

Sales Force Growth Plan Plan to expand U.S. direct sales force and increase payer awareness to drive future revenue growth.

Peer Comparison

Revenue (TTM)

OMI

$2.76B

-41.0%

INGN

$348.67M

+3.9%

VMD

$270.28M

+20.5%

Gross Margin (Latest Quarter)

OMI

93.9%

-2.1pp

FHTX

91.3%

-245.3pp

SGHT

87.3%

+2.5pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
VMD	$379.32M	24.9	10.9%	7.4%
CERS	$345.91M	-22.0	-26.4%	43.7%
FHTX	$291.15M	-4.2	88.3%	20.8%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

9.1%

Steady Growth

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:Apr 29, 2026

EPS:-$0.52

Revenue:$14.06M

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data